US 2016/0250267 A1 · ONCOLYTIC HSV VECTOR

Abstract

The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

Claims40

Dependent claims

A recombinant oncolytic Herpes Simplex Virus (oHSV), comprising:

(a) a non-HSV ligand displayed on the surface of the oHSV capsid, which is specific for a molecule present on the surface of a cancer cell and;
(b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication in normal (non-cancerous) cells.

Dependencies are inferred from the claim text.

Facts

Application

15/032,958Filed 28 Oct 2014

Priority

28 Oct 2013

Published

1 Sep 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 35/763
Viruses; Subviral particles; Bacteriophages: herpes virus
A61P 35/00
Antineoplastic agents
C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
C12N 7/00
Viruses

Oncolytic hsv vector

Life of this patent

Oncolytic hsv vector

Life of this patent

Abstract

Claims40